---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-105245"
form_type: "8-K"
ticker: "RLMD"
cik: "0001553643"
company_name: "RELMADA THERAPEUTICS, INC."
filed_at: "2024-12-04T23:59:59+00:00"
generated_at: "2026-05-29T08:38:01.149584+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Relmada Phase 3 Reliance II trial for REL-1017 in MDD deemed futile at interim analysis

## Summary
- DMC interim analysis indicates Reliance II is futile, unlikely to meet primary efficacy endpoint with statistical significance.
- No new safety signals reported; DMC did not identify any safety concerns.
- Relmada to evaluate next steps for REL-1017 program; continues development of REL-P11 for metabolic disease.
- Cash and cash equivalents ~$54.1M as of Sep 30, 2024, providing runway.
- Sergio Traversa, CEO, expressed disappointment and gratitude to participants.

## SEC filing metadata
- accession: 0001213900-24-105245
- form_type: 8-K
- ticker: RLMD
- cik: 0001553643
- company_name: RELMADA THERAPEUTICS, INC.
- filed_at: 2024-12-04T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/0001213900-24-105245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1553643/000121390024105245/ea0223563-8k_relmada.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-105245
- JSON: https://secwatch.observer/filing/0001213900-24-105245.json
- Plain text: https://secwatch.observer/filing/0001213900-24-105245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.